On September 2, 2026 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) ("Can-Fite" or the "Company"), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, reported the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,591,738 American Depositary Shares (ADSs), having an exercise price of $5.00 per ADS, issued by Can-Fite in March 2026, at a reduced exercise price of $2.50 per ADS. The ADSs representing ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form F-3 (File No. 333-294760). The closing of the offering is expected to occur on or about September 3, 2026, subject to satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

In consideration for the immediate exercise of the warrants for cash, Can-Fite will issue new unregistered warrants to purchase up to 3,183,476 ADSs. The new warrants will have an exercise price of $2.50 per ADS, will be immediately exercisable until the twenty-four month anniversary of the effective date of the Resale Registration Statement.

The gross proceeds to Can-Fite from the exercise of the warrants are expected to be approximately $4.0 million, prior to deducting placement agent fees and offering expenses. The Company intends to use the net proceeds for funding research and development and clinical trials and for other working capital and general corporate purposes.

The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the "1933 Act"), and, along with the ADSs issuable upon exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ("SEC") or an applicable exemption from such registration requirements. Can-Fite has agreed to file a registration statement with the SEC covering the resale of the shares of ADSs issuable upon exercise of the new warrants (the "Resale Registration Statement").

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

(Press release, Can-Fite BioPharma, SEP 2, 2026, View Source [SID1234670530])

On September 2, 2026 Abeona Therapeutics Inc. (Nasdaq: ABEO) reported that members of its management team will participate in upcoming investor conferences in September 2026:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cantor Global Healthcare Conference 2026: Fireside chat on Wednesday, September 9, 2026, at 8:00 a.m. ET and investor meetings.

H.C. Wainwright 28th Annual Global Investment Conference: Company presentation on Tuesday, September 15, 2026, at 12:00 p.m. ET and investor meetings.

Morgan Stanley 24th Annual Global Healthcare Conference: Fireside chat on Wednesday, September 16, 2026, at 11:30 a.m. ET and investor meetings.

Live webcasts of the fireside chats and company presentation can be accessed on the Investors section of the Abeona website under "Events" at View Source, where replays of available events will also be accessible for a limited time.

(Press release, Abeona Therapeutics, SEP 2, 2026, View Source [SID1234670527])

On September 2, 2026 Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) and Plectonic Biotech reported a research collaboration to explore a novel immunotherapy approach for solid tumors. The collaboration addresses key challenges that have so far limited the successful application of traditional T cell engager therapies in solid tumors by combining Plectonic’s programmable LOGIBODY technology with Evotec’s proprietary BiTco platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Plectonic’s LOGIBODY technology engineers DNA-protein therapeutics designed to recognize tumors through a highly specific combination of tumor-associated antigens before engaging T cells. Unlike conventional T cell engagers, LOGIBODY molecules require simultaneous binding to a predefined multi-antigen tumor signature to trigger T cell activation. This logic-gated approach represents a novel drug class aimed at improving treatment precision, reducing activation in healthy tissues and potentially broadening the therapeutic window.

Evotec’s BiTco platform is based on a proprietary, non-blocking CD2 antibody designed to provide an additional costimulatory signal to T cells, enhancing their activity and persistence within the tumor microenvironment. The antibody targets a unique CD2 epitope while preserving its natural interactions, enabling BiTco to strengthen T cell responses, enhance tumor cell killing mediated by T cell engagers, and delay T cell exhaustion.

By combining highly selective tumor recognition and enhanced T-cell activation, the companies will explore whether their integrated technologies can improve both the precision and potency of T-cell-engaging approaches in solid tumors. Under the terms of the agreement, the collaboration will generate preclinical proof-of-concept data to evaluate the potential of this new generation of T-cell-engaging approaches.

Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, said:

"T cell engagers have demonstrated significant promise in oncology in blood cancers, yet challenges remain in extending their clinical success to solid tumors, which represent approximately 90 percent of all cancers. Through this collaboration, we aim to evaluate the potential of combining our proprietary BiTco platform with Plectonic’s LOGIBODY technology and explore new strategies to enhance T cell engager activity in solid tumors. Our CD2-based co-stimulation approach is an ideal component for this effort or any TCE development strategy that seeks an effective source of T cell co-stimulation in the solid tumor setting."

Dr. Klaus Wagenbauer, CEO and Founder of Plectonic Biotech, added:

"This collaboration with Evotec highlights the broad potential and modularity of our LOGIBODY technology to engineer logic-gated T-cell-engaging biologics and explore novel multi-specific designs. By combining our complementary technologies, we have the opportunity to enable highly precise and controlled immune activation at the tumor. Together, we look forward to investigating this next-generation modality and exploring new ways to address long-standing challenges in tumor selectivity and safety that have limited the effectiveness of T cell engagers in solid tumor indications."

Plectonic has demonstrated the modularity of its LOGIBODY technology in preclinical studies across both liquid and solid tumors, utilizing dual-targeting and co-stimulatory therapeutic strategies. Evotec recently published preclinical research on its BiTco platform, providing proof-of-concept for CD2-mediated T cell co-stimulation in combination with T cell engager approaches.

(Press release, Evotec, SEP 2, 2026, View Source [SID1234670497])

On September 2, 2026 Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, reported that Athena Countouriotis, M.D., Chair, President and CEO is scheduled to present and host investor meetings at the Wells Fargo 21st Annual Healthcare Conference taking place in Everett, Massachusetts from September 8–10, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the company’s participation are as follows:
Event: Presentation
Date: Wednesday, September 9, 2026
Presentation Time: 11:00 a.m. ET / 8:00 a.m. PT

A live webcast of the presentation will be accessible on the company’s website, www.avenzotx.com, under the News section and an archived recording will be available on the website for 90 days following the presentation.

(Press release, Avenzo Therapeutics, SEP 1, 2026, View Source [SID1234670528])

On September 1, 2026 DnaK Therapeutics and GATC Health Corp reported a collaboration to use GATC’s proprietary artificial intelligence platform to evaluate and prioritize 16 innovative, potential cancer drug candidates. By applying GATC’s predictive AI platform early in the drug-development process, DnaK will be able to prioritize the most promising molecules for preclinical studies, obviating months off traditional experimental timelines and saving millions of dollars in research and development costs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

DnaK Therapeutics is pioneering potential treatments that target DnaK, a protein produced by tumor-associated bacteria that cause chemotherapy resistance in colorectal and gastric cancers, among others. The Company is investigating drug candidates that could consequently and substantially improve the effectiveness of existing cancer treatments by blocking or inhibiting DnaK.

"Drug development requires difficult decisions early in the process about where to invest time and resources," said Dr. Rahul Gupta, president of GATC Health and former director of the White House Office of National Drug Control Policy. "The earlier we can provide useful information about a candidate’s potential risks and benefits, the better those decisions can be before substantial resources are committed to laboratory studies and clinical development. We are honored and excited to have the opportunity to work with Dr. Gallo, one of the world’s most accomplished and renowned scientists, and the visionary leadership team of DnaK."

"We have a number of potentially viable drug candidates, but we need to determine which are the most beneficial, effective, and safest before we invest substantial resources," said Dr. Robert C. Gallo, co-founder of DnaK Therapeutics. "If this technology can give us useful information earlier and help us focus on the most promising candidates, it could considerably accelerate bringing these potentially groundbreaking drugs to the next stage of our research."

GATC will evaluate DnaK’s 16 potential drug candidates using its predictive AI technology and Derisq reports, which assess factors including potential safety, efficacy and off-target effects. The analysis will help identify a smaller group of high-priority candidates for experimental testing, with initial results expected this fall. DnaK will use those findings as it works toward selecting a lead development candidate. If successful, DnaK and GATC expect to explore opportunities to apply the approach to additional drug targets and therapeutic programs.

In January 2025, DnaK Therapeutics was accepted into the University of South Florida’s USF CONNECT’s Tampa Bay Technology Incubator (TBTI). Through TBTI, DnaK has access to specialized facilities, shared laboratory resources, mentorship, business development support and connections designed to help move research toward commercialization.

(Press release, DnaK Therapeutics, SEP 1, 2026, View Source [SID1234670526])